Latest Cancer News

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions (12-1-2016)

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response [...]

Darzalex® Approved for Additional Indications in Multiple Myeloma (11-29-2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA indication also requires that daratumumab be used in combination with lenalidomide and dexamethasone, or in combination with bortezomib and [...]

Opdivo Approved for Advanced Head and Neck Cancer (11-28-2016)

The United States Food and Drug Administration (FDA) has approved the immunotherapeutic agent, Opdivo® (nivolumab) for the treatment of advanced head and neck cancer. Specifically,  the indication is for the treatment of squamous cell carcinoma of the head and neck cancer (SCCHN) that has spread to distant sites in the [...]

It’s GERD Awareness Week–November 20th (11-20-2016)

It’s that time of year again when there is a tendency to overindulge in a mélange of delicious foods. Although many people may only suffer discomfort from over eating, another group of people suffer from the far more troublesome and chronic disorder of GERD—and it isn’t just over the holidays, [...]

FDA Priority Review Granted for Midostaurin in Leukemia (11-17-2016)

The United States Food and Drug Administration (FDA) has granted priority review to PKC412 (midostaurin) in the treatment of newly diagnosed acute myeloid leukemia (AML) with the FLT3 mutation, as well as for the treatment of advanced systemic mastocytosis (SM). The diagnostic test to detect the FLT3 mutation has also [...]

Aromatase Inhibitor–Associated Joint Pain Tends to Resolve Upon Treatment Completion (11-15-2016)

A class of drugs known as aromatase inhibitors (AI) commonly used in the management of estrogen receptor-positive (ER+) breast cancer are associated with troublesome joint pain. In fact, as many as half of women on AI therapy experience joint pain, and 20% become non-compliant with their AI therapy because of [...]

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (11-9-2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to [...]

Inflammatory Bowel Disease: More Common than Previously Thought (11-8-2016)

A recent report reveals that Crohn’s disease and ulcerative colitis, collectively known as inflammatory bowel disease (IBD), effect an estimated 3.1 million (1.3%) U.S. adults.  This is an increase from a report released in 1999 estimating that 1.8 million Americans (0.9%) were diagnosed with IBD. IBD is an immune-mediated chronic [...]

Personalized Lung Cancer Care & Precision Medicine (11-8-2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then [...]

Chemotherapy Before Surgery Improves Treatment of Sarcoma (11-7-2016)

For patients with localized soft-tissue sarcoma of the trunk or extremities who are high risk for relapse, the use of anthracycline plus ifosfamide chemotherapy prior to surgery appears to improve survival. Chemotherapy administered before surgery is called neoadjuvant therapy and has not previously been demonstrated to improve outcomes in soft [...]

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (10-31-2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy. Researchers continue to study new approaches for improving the outcomes of all women affected by ovarian cancer but progress [...]

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (10-27-2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine [...]

Next Page »